AACR Journals

Welcome to the official LinkedIn page for the AACR Journals! Connect with our community to keep up to date with AACR Journals’ content, researchers, events, and opportunities.

Recently published in Cancer Research Communications: The Tumor Immune Microenvironment and Therapeutic Efficacy of Trastuzumab Deruxtecan in Gastric Cancer https://brnw.ch/21wRsPR Do HER2 expression levels and immune cell characteristics affect response to trastuzumab deruxtecan (T-DXd)? This biomarker study aimed to explore HER2 expression and immune cell infiltration in relation to the clinical efficacy of T-DXd in patients with gastric cancer and verify whether T-DXd exhibits immunomodulatory activity. The results suggest that HER2 expression levels and tumor characteristics before the initiation of T-DXd may correlate with the efficacy of the drug. #TDXd #openaccess

Have you picked your favorite 2024 Cancer Research cover? There’s still time to cast your vote to help us recognize the journal’s best art of the year. Voting ends on Monday, April 7. https://brnw.ch/21wRsy0

Attending the American Association for Cancer Research Annual Meeting? Register for the 2025 Professional Advancement Session “Productive Peer Review: Improving Science while Avoiding Common Pitfalls,” taking place on April 28. Drs. Christine Iacobuzio-Donahue and Christine M. Lovly will moderate this interactive Professional Advancement Session. https://lnkd.in/eyScJnKJ #AACR25

Recently published in Cancer Research Communications: First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies https://brnw.ch/21wRr0t Although the development of immune checkpoint inhibitors has altered the treatment paradigm for many cancers, only a minority of patients receive durable benefit from current immune-oncology therapies, pointing to an urgent need for the identification of additional immune checkpoints and novel biology to be addressed by new therapies. CD200R1 was identified as a promising therapeutic target for cancer, and this article reports the results of a phase I study evaluating 23ME-00610, a novel anti-CD200R1 mAb that antagonizes CD200-mediated immune suppression. #openaccess

Recently published in Cancer Research Communications: A Cost-Effective Two-Step Approach for Multi-Cancer Early Detection in High-Risk Populations https://lnkd.in/eXkBG8vJ Large-scale screening inevitably leads to significant financial burdens on the health care system—a key factor constraining nationwide cancer screenings. In this study, the authors focused on developing a two-step multi-cancer early detection (MCED) approach that is cost-effective and performs comparably to next-generation sequencing (NGS)–based MCED approaches. Their approach not only maintains comparable performance but substantially alleviates financial strains compared with NGS-based MCED tests for population-wide screenings. #CancerEarlyDetection #CancerScreening #openaccess

Read the March 15 issue of Cancer Research, now online. https://brnw.ch/21wRnZJ

New from Cancer Immunology Research: Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration Single-cell transcriptomic analysis of serial biopsies predicts that anti–PD-1/PD-L1 therapy concurrent with radiotherapy and anti-CTLA4/TIGIT therapy concurrent/adjuvant with radiotherapy would be effective combination treatment regimens, potentially guiding future therapeutic strategies in esophageal cancer treatment. Read the article: https://brnw.ch/21wRnKP

From the March issue of Blood Cancer Discovery: Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population. Read the research brief: https://brnw.ch/21wRkBZ

Submit your paper to Cancer Research's special series: Driving Cancer Discoveries with Computational Research, Data Science, and Machine Learning/AI. We are interested in papers with a major focus on: ?? Bioinformatics ?? Mathematics ?? AI/machine learning ?? Systems biology ?? Data science ?? 'Omics Learn more: https://brnw.ch/21wQ2b7 Submit now: https://brnw.ch/21wQ2b6